Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Front Physiol ; 9: 394, 2018.
Article in English | MEDLINE | ID: mdl-29740333

ABSTRACT

This review summarizes the latest advances in knowledge on the effects of flavonoids on renal function in health and disease. Flavonoids have antihypertensive, antidiabetic, and antiinflammatory effects, among other therapeutic activities. Many of them also exert renoprotective actions that may be of interest in diseases such as glomerulonephritis, diabetic nephropathy, and chemically-induced kidney insufficiency. They affect several renal factors that promote diuresis and natriuresis, which may contribute to their well-known antihypertensive effect. Flavonoids prevent or attenuate the renal injury associated with arterial hypertension, both by decreasing blood pressure and by acting directly on the renal parenchyma. These outcomes derive from their interference with multiple signaling pathways known to produce renal injury and are independent of their blood pressure-lowering effects. Oral administration of flavonoids prevents or ameliorates adverse effects on the kidney of elevated fructose consumption, high fat diet, and types I and 2 diabetes. These compounds attenuate the hyperglycemia-disrupted renal endothelial barrier function, urinary microalbumin excretion, and glomerular hyperfiltration that results from a reduction of podocyte injury, a determinant factor for albuminuria in diabetic nephropathy. Several flavonoids have shown renal protective effects against many nephrotoxic agents that frequently cause acute kidney injury (AKI) or chronic kidney disease (CKD), such as LPS, gentamycin, alcohol, nicotine, lead or cadmium. Flavonoids also improve cisplatin- or methotrexate-induced renal damage, demonstrating important actions in chemotherapy, anticancer and renoprotective effects. A beneficial prophylactic effect of flavonoids has been also observed against AKI induced by surgical procedures such as ischemia/reperfusion (I/R) or cardiopulmonary bypass. In several murine models of CKD, impaired kidney function was significantly improved by the administration of flavonoids from different sources, alone or in combination with stem cells. In humans, cocoa flavanols were found to have vasculoprotective effects in patients on hemodialysis. Moreover, flavonoids develop antitumor activity against renal carcinoma cells with no toxic effects on normal cells, suggesting a potential therapeutic role in patients with renal carcinoma.

2.
Exp Biol Med (Maywood) ; 241(5): 550-6, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26674221

ABSTRACT

This study assessed the effects of thyroid hormones on the enzymes involved in l-arginine metabolism and the metabolites generated by the different metabolic pathways. Compounds of l-arginine metabolism were measured in the kidney, heart, aorta, and liver of euthyroid, hyperthyroid, and hypothyroid rats after 6 weeks of treatment. Enzymes studied were NOS isoforms (neuronal [nNOS], inducible [iNOS], and endothelial [eNOS]), arginases I and II, ornithine decarboxylase (ODC), ornithine aminotransferase (OAT), and l-arginine decarboxylase (ADC). Metabolites studied were l-arginine, l-citrulline, spermidine, spermine, and l-proline. Kidney heart and aorta levels of eNOS and iNOS were augmented and reduced (P < 0.05, for each tissue and enzyme) in hyper- and hypothyroid rats, respectively. Arginase I abundance in aorta, heart, and kidney was increased (P < 0.05, for each tissue) in hyperthyroid rats and was decreased in kidney and aorta of hypothyroid rats (P < 0.05, for each tissue). Arginase II was augmented in aorta and kidney (P < 0.05, for each tissue) of hyperthyroid rats and remained unchanged in all organs of hypothyroid rats. The substrate for these enzymes, l-arginine, was reduced (P < 0.05, for all tissues) in hyperthyroid rats. Levels of ODC and spermidine, its product, were increased and decreased (P < 0.05) in hyper- and hypothyroid rats, respectively, in all organs studied. OAT and proline levels were positively modulated by thyroid hormones in liver but not in the other tissues. ADC protein levels were positively modulated by thyroid hormones in all tissues. According to these findings, thyroid hormone treatment positively modulates different l-arginine metabolic pathways. The changes recorded in the abundance of eNOS, arginases I and II, and ADC protein in renal and cardiovascular tissues may play a role in the hemodynamic and renal manifestations observed in thyroid disorders. Furthermore, the changes in ODC and spermidine might contribute to the changes in cardiac and renal mass observed in thyroid disorders.


Subject(s)
Arginine/metabolism , Hyperthyroidism/pathology , Hypothyroidism/pathology , Kidney/metabolism , Myocardium/metabolism , Thyroid Hormones/metabolism , Animals , Aorta/metabolism , Liver/metabolism , Male , Metabolic Networks and Pathways/drug effects , Rats, Wistar
3.
Am J Hypertens ; 28(12): 1464-72, 2015 Dec.
Article in English | MEDLINE | ID: mdl-25907224

ABSTRACT

BACKGROUND: This study analyzed the effects of chronic administration of N[omega]-hydroxy-nor-l-arginine (nor-NOHA), an inhibitor of arginase, on the hemodynamic, oxidative stress, morphologic, metabolic, and renal manifestations of hyperthyroidism in rats. METHODS: Four groups of male Wistar rats were used: control, nor-NOHA-treated (10 mg/kg/day), thyroxine (T4)-treated (75 µg/rat/day), and thyroxine- plus nor-NOHA-treated rats. All treatments were maintained for 4 weeks. Body weight, tail systolic blood pressure (SBP), and heart rate (HR) were recorded weekly. Finally, morphologic, metabolic, plasma, and renal variables were measured. Arginase I and II protein abundance and arginase activity were measured in aorta, heart, and kidney. RESULTS: The T4 group showed increased arginase I and II protein abundance, arginase activity, SBP, HR, plasma nitrates/nitrites (NOx), brainstem and urinary isoprostanes, proteinuria and cardiac and renal hypertrophy in comparison to control rats. In hyperthyroid rats, chronic nor-NOHA prevented the increase in SBP and HR and decreased proteinuria in association with an increase in plasma NOx and a decrease in brainstem and urinary isoprostanes. In normal rats, nor-NOHA treatment did not significantly change any hemodynamic, morphologic, or renal variables. Acute nor-NOHA administration did not affect renal or systemic hemodynamic variables in normal or T4-treated rats. CONCLUSION: Hyperthyroidism in rats is associated with the increased expression and activity of arginase in aorta, heart, and kidney. Chronic arginase inhibition with nor-NOHA suppresses the characteristic hemodynamic manifestations of hyperthyroidism in association with a reduced oxidative stress. These results indicate an important role for arginase pathway alterations in the cardiovascular and renal abnormalities of hyperthyroidism.


Subject(s)
Arginase/antagonists & inhibitors , Arginine/analogs & derivatives , Hypertension/drug therapy , Hyperthyroidism/drug therapy , Animals , Arginase/metabolism , Arginine/pharmacology , Arginine/therapeutic use , Blood Pressure , Brain Stem/metabolism , Drug Evaluation, Preclinical , Heart Rate , Hypertension/etiology , Hypertension/metabolism , Hyperthyroidism/complications , Hyperthyroidism/metabolism , Isoprostanes/urine , Male , Nitric Oxide/blood , Random Allocation , Rats, Wistar , Renal Circulation/drug effects , Thyroid Hormones/blood
4.
Tumour Biol ; 35(8): 7799-805, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24816945

ABSTRACT

This study evaluated the effects of the pro-oxidant buthionine sulfoximine (BSO) and of the interaction between BSO and TETRAC, an antagonist of αvß3 integrin, on tumor development and aminopeptidase (AP) activity in a murine model of implanted Lewis's carcinoma. Male CBA-C57 mice were untreated (controls) or treated with BSO (222 mg/100 mL in drinking water), TETRAC (10 mg/kg/day, i.p.), or BSO + TETRAC. BSO for 28 days and TETRAC were given for the last 20 days. Mice were subcutaneously inoculated with 1 × 10(6) Lewis carcinoma 3LL cells into the dorsum. Study variables were tumor weight (TW); Hb, as index of tumor-mediated angiogenesis; vascular endothelial growth factor (VEGF) protein abundance; protein carbonyl content; α-tubulin abundance; and GluAp, AlaAp, and AspAp activities. BSO produced a major decrease in TW (203 ± 18 mg) with respect to controls (365 ± 26) and a reduction in Hb content. The TETRAC group also showed marked reductions in TW (129 ± 15) and Hb concentration associated with a reduced VEGF content. The BSO + TETRAC group showed a major TW reduction (125 ± 13); although, the difference with the TETRAC group was not significant. BSO treatment increased protein carbonyl and tubulin abundance in comparison to controls. The activity of all APs was increased in the three experimental groups and was strongly and negatively correlated with TW. In conclusion, administration of BSO reduced the TW, which inversely correlated with protein carbonyl content, suggesting a loss of microtubule polymerization. The finding of a negative correlation between TW and AP activity opens up new perspectives for the study of APs as tumor growth modulators.


Subject(s)
Aminopeptidases/metabolism , Buthionine Sulfoximine/pharmacology , Carcinoma, Lewis Lung/drug therapy , Protein Carbonylation , Tubulin/metabolism , Animals , Carcinoma, Lewis Lung/metabolism , Carcinoma, Lewis Lung/pathology , Cells, Cultured , Male , Mice , Mice, Inbred CBA , Oxidative Stress , Thyroxine/analogs & derivatives , Thyroxine/pharmacology
5.
Am J Hypertens ; 25(6): 629-35, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22223042

ABSTRACT

Oxidative stress contributes to the development of several cardiovascular diseases, including diabetes, renal insufficiency, and arterial hypertension. Animal studies have evidenced the association between higher blood pressure (BP) and increased oxidative stress, and treatment with antioxidants has been shown to reduce BP, while BP reduction due to antihypertensive drugs is associated with reduced oxidative stress. In 2000, it was first reported that oxidative stress and arterial hypertension were produced in normal Sprague-Dawley rats by oral administration of buthionine sulfoximine (BSO), which induces glutathione (GSH) depletion, indicating that oxidative stress may induce hypertension. The contribution of several potential pathogenic factors has been evaluated in the BSO rat model, the prototype of oxidative stress-induced hypertension, including vascular reactivity, endothelium-derived factors, renin-angiotensin system activity, TXA(2)-PGH(2) production, sodium sensitivity, renal dopamine-induced natriuresis, and sympathetic tone. This review summarizes the main factors implicated in the pathogenesis of BSO-induced hypertension and the alterations associated with GSH depletion that are related to renal function or BP control.


Subject(s)
Buthionine Sulfoximine/pharmacology , Cardiovascular System/physiopathology , Glutathione/deficiency , Kidney/physiopathology , Oxidative Stress/drug effects , Animals , Antioxidants/pharmacology , Blood Pressure/drug effects , Blood Pressure/physiology , Buthionine Sulfoximine/adverse effects , Disease Models, Animal , Glutathione/drug effects , Glutathione/metabolism , Hypertension/chemically induced , Hypertension/metabolism , Hypertension/physiopathology , Mice , Oxidative Stress/physiology , Rats , Rats, Sprague-Dawley
6.
Exp Biol Med (Maywood) ; 237(12): 1457-61, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23354404

ABSTRACT

The isolated perfused rat kidney technique is one of the most widely used methods in renal research. It has proven useful to investigate biochemical, physiological, pharmacological and pathophysiological aspects of renal function, allowing variables to be changed in a controlled manner and eliminating systemic influences. This study was designed to test a new surgical procedure to isolate both kidneys for their utilization in this technique, mainly as a vascular preparation. The viability of the resulting preparations was compared with those obtained by the classical method, analyzing the responsiveness to the vasoconstrictor phenylephrine and to the endothelium-dependent vasodilator acetylcholine. Vascular reactivity was evaluated under normal conditions and in endothelium-denuded preparations. The dose response curves to phenylephrine and to acetylcholine were similar in the three experimental groups, regardless of the procedure used for kidney isolation, in both endothelium-intact and endothelium-denuded preparations. We give a step-by-step description of the isolation method and key points for the success of the technique. In conclusion, the surgical procedure proposed in this paper reduces the number of animals required by half and hence reduces the cost of the experiments. This novel procedure is of special interest for acute experiments to test new vasoactive drugs and for analysis of the action mechanisms of these drugs. It could also be used in chronic studies or in genetically modified animals when different experimental protocols are performed on the left and right kidneys and to improve the accuracy of the results by analyzing cases in duplicate.


Subject(s)
Acetylcholine/pharmacology , Kidney/blood supply , Kidney/surgery , Nephrectomy/methods , Phenylephrine/pharmacology , Vasoconstrictor Agents/pharmacology , Vasodilator Agents/pharmacology , Animals , Kidney/physiopathology , Male , Rats , Rats, Wistar , Vasoconstriction/drug effects , Vasodilation/drug effects
7.
J Endocrinol ; 213(1): 25-36, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22043064

ABSTRACT

Thyroid disorders are among the most common endocrine diseases and affect virtually all physiological systems, with an especially marked impact on cardiovascular and renal systems. This review summarizes the effects of thyroid hormones on the renin-angiotensin system (RAS) and the participation of the RAS in the cardiovascular and renal manifestations of thyroid disorders. Thyroid hormones are important regulators of cardiac and renal mass, vascular function, renal sodium handling, and consequently blood pressure (BP). The RAS acts globally to control cardiovascular and renal functions, while RAS components act systemically and locally in individual organs. Various authors have implicated the systemic and local RAS in the mediation of functional and structural changes in cardiovascular and renal tissues due to abnormal thyroid hormone levels. This review analyzes the influence of thyroid hormones on RAS components and discusses the role of the RAS in BP, cardiac mass, vascular function, and renal abnormalities in thyroid disorders.


Subject(s)
Cardiovascular Diseases/etiology , Kidney Diseases/etiology , Renin-Angiotensin System/physiology , Thyroid Diseases/complications , Thyroid Diseases/etiology , Animals , Cardiovascular Diseases/physiopathology , Kidney Diseases/physiopathology , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...